Singapore markets closed

Geron Corporation (0IV3.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
4.0900+0.0850 (+2.12%)
As of 07:09PM BST. Market open.
Full screen
Previous close4.0050
Open0.0000
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.0000 - 0.0000
52-week range
Volume4,800
Avg. volume12,482
Market cap7.056M
Beta (5Y monthly)0.61
PE ratio (TTM)N/A
EPS (TTM)-0.3590
Earnings date02 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights

    FOSTER CITY, Calif., May 02, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results and business highlights for the first quarter 2024.

  • Business Wire

    Geron to Announce First Quarter 2024 Financial Results on May 2, 2024

    FOSTER CITY, Calif., April 25, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. ET the same day.

  • Business Wire

    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    FOSTER CITY, Calif., April 18, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.